The Chief Executive of German biotechnology company IDT Biologika, Juergen Betzing, said the company plans to start a phase II trial of its experimental COVID-19 vaccine by the end of the year, Reuters news agency reported on Monday.
IDT Biologika is a German contract development and manufacturing company focussed on the development and manufacture of live viral vaccines.
Betzing was quoted as saying at a news conference that the company hopes to be able to apply for approval in 2021.
"If all clinical tests are successful, we could apply for an accelerated approval at the end of 2021," Betzing added.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100